Zivo Bioscience, Inc. (ZIVO): who owns it and who trades it
As of Oct 30, 2026, ZIVO insiders reported 7 purchases worth $575K in the last 12 months. The largest buyer was Strome Investment Management Lp (Other), with $200K.
Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, ZIVO insiders reported $575K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | Strome Investment Management Lp +2 | Other | Purchase | 100,000 | $2.00 | $200K | Form 4 |
| Feb 27, 2026 | Laith L Yaldoo | Director | Purchase | 1,543 | $9.72 | $15K | Form 4 |
| Feb 12, 2026 | Strome Group, Inc. +2 | Other | Purchase | 20,000 | $9.77 | $195K | Form 4 |
| Feb 10, 2026 | Laith L Yaldoo | Director | Purchase | 2,434 | $10.27 | $25K | Form 4 |
| Jan 26, 2026 | Alison A Cornell | Director | Purchase | 11,709 | $8.54 | $100K | Form 4 |
| Jan 14, 2026 | Christopher D. Maggiore | Director | Purchase | 1,766 | $8.49 | $15K | Form 4 |
| Nov 28, 2025 | Laith L Yaldoo | Director | Purchase | 2,777 | $9.00 | $25K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Strome Investment Management Lp | Other | $200K | – | Apr 17, 2026 |
| Strome Group, Inc. | Other | $195K | – | Feb 12, 2026 |
| Alison A Cornell | Director | $100K | – | Jan 26, 2026 |
| Laith L Yaldoo | Director, 10% owner | $65K | – | Feb 27, 2026 |
| Christopher D. Maggiore | Director, 10% owner | $15K | – | Jan 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ZIVO short interest
7,729 ZIVO shares are sold short. Over the last 12 reports the number of shares short went down 13%.
As of Oct 30, 2026, 7,729 ZIVO shares were sold short, down 1.6% from the report before. At the average daily volume of 910 shares, buying them all back would take about 8.5 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7,729 | – | -2% | 910 | 8.5 |
| Oct 15, 2026 | 7,856 | – | -2% | 2,001 | 3.9 |
| Sep 30, 2026 | 7,977 | – | -1% | 1,137 | 7.0 |
| Sep 15, 2026 | 8,019 | – | +3% | 1,017 | 7.9 |
| Aug 31, 2026 | 7,815 | – | -4% | 757 | 10.3 |
| Aug 14, 2026 | 8,164 | – | -2% | 181 | 45.1 |
| Jul 31, 2026 | 8,329 | – | +7% | 1,745 | 4.8 |
| Jul 15, 2026 | 7,811 | – | -3% | 1,360 | 5.7 |
| Jun 30, 2026 | 8,031 | – | -0% | 3,014 | 2.7 |
| Jun 15, 2026 | 8,071 | – | -4% | 1,240 | 6.5 |
| May 29, 2026 | 8,397 | – | -5% | 809 | 10.4 |
| May 15, 2026 | 8,871 | 0.23% | -36% | 5,747 | 1.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Zivo Bioscience company events
Zivo Bioscience filed 2 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Mar 30, 2026.
- Mar 30, 2026LeadershipWilliam A. Sullivan announced his intention to resign as Interim Chief Financial Officer of Zivo Bioscience, Inc., effective Monday, March 30, 2026. Filing
- Dec 23, 2025LeadershipKeith R. Marchiando announced his intention to resign as Chief Financial Officer of Zivo Bioscience, Inc. effective immediately and end his employment with the Company effective December 31, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Questions about Zivo Bioscience, Inc. (ZIVO) stock
Are ZIVO insiders buying or selling?
In the last 12 months, ZIVO insiders reported 7 open-market purchases worth $575K and no sales. The latest trade was on Apr 17, 2026. See every trade.
What is the short interest in ZIVO?
As of Oct 30, 2026, 7,729 ZIVO shares were sold short, down 1.6% from the report before. At the average daily volume of 910 shares, buying them all back would take about 8.5 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.